Downregulation of PGI2 pathway in Pulmonary Hypertension Group-III patients

Pulmonary hypertension (PH) is characterized by a progressive increase in mean pulmonary artery pressure (mPAP>20 mmHg) and vascular resistance due to sustained pulmonary artery vasoconstriction [1, 2]. The clinical classification of PH is intended to categorize multiple clinical conditions into five groups. Depending on this classification, PH Group-III is defined as PH due to lung diseases and/or hypoxia. Common lung diseases associated with PH are chronic obstructive pulmonary disease (COPD), interstitial lung disease and combined pulmonary fibrosis and emphysema [3].

Source: Prostaglandins, Leukotrienes and Essential Fatty Acids - July 4, 2020 Category: Biomedical Science Authors: Gulsev Ozen, Yasmine Amgoud, Heba Abdelazeem, Salma Mani, Chabha Benyahia, Amel Bouhadoun, Alexy Tran-Dinh, Yves Castier, Alice Guyard, Dan Longrois, Adam M. Silverstein, Xavier Norel Source Type: research